Every material Form 8-K Phio Pharmaceuticals Corp. has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Phio Pharmaceuticals reported a third-quarter 2026 net loss of $4.2 million, up from $2.4 million a year earlier, as research and development costs for its PH-762 program rose sharply. Cash and cash equivalents fell to $10.6 million at September 30, 2026, from $21.0 million at December 31, 2025, and the company's stockholders' equity declined to $8.6 million, so shareholders face a larger loss and a smaller cash balance.
Q3 2026 research and development expenses were $3.0 million, up $1.9 million or 159% from the prior-year quarter, driven mainly by nonclinical toxicology, drug substance and clinical supply costs.
Nine-month 2026 net loss was $12.3 million, compared with $6.3 million in the same period of 2025.
Cash and cash equivalents were $10.6 million at September 30, 2026, versus $21.0 million at December 31, 2025.
The company expects FDA feedback on its submission by the end of November 2026 and plans to start the Phase 2b study of PH-762 in the first quarter of 2027.
Phio Pharmaceuticals announced on October 13, 2026 that it successfully released its first commercial-scale cGMP batch of PH-762 drug substance. The batch will move on to final drug product steps for the planned Phase 2b clinical study, which the company expects to start in the first quarter of 2027. The filing reports an operational milestone and includes no financial results.
Batch was manufactured to established specifications and confirmed by a Certificate of Analysis and Certificate of Compliance
Planned Phase 2b clinical study of PH-762 is expected to begin in the first quarter of 2027
CEO Robert Bitterman said the work began about 16 months ago and is intended to mitigate key development and manufacturing risks
At its 2026 Annual Meeting on September 28, 2026, Phio Pharmaceuticals stockholders approved an amendment that raises the shares available under its 2020 Long Term Incentive Plan by 1,500,000 to a total of 2,452,017. Stockholders also re-elected six directors and ratified Grant Thornton, LLP as the independent auditor for 2026. The larger share pool allows more shares to be issued under the plan than before.
Plan Amendment approved; shares available under the 2020 Plan rise by 1,500,000 to 2,452,017.
Plan proposal vote: 1,155,945 for, 194,070 against, 34,468 abstained, and 3,823,097 broker non-votes.
All six director nominees elected, including Robert J. Bitterman, to serve until the 2027 Annual Meeting; Grant Thornton ratified with 5,087,608 votes for.
5,207,580 shares were present of 11,617,250 outstanding at the August 4, 2026 record date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Phio Pharmaceuticals Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →